Literature DB >> 10199787

Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy.

C Hansen1, R Rouhi, G Förster, G J Kahaly.   

Abstract

Accumulation of interstitial glycosaminoglycans (GAG) in orbital tissue of patients with Graves' ophthalmopathy (GO) leads to edema, increased orbital pressure, and proptosis. In this study, a new, highly sensitive, high performance liquid chromatography method was developed to determine the altered concentration and biochemical composition of different GAG polymers in orbital connective tissue of 27 GO patients and 18 controls. GAG were isolated by tissue homogenization and digestion, followed by sequential enzymatic GAG hydrolysis and high performance liquid chromatographic analysis of the resulting alpha,beta-unsaturated disaccharides. High recovery rates of 78 +/- 6% (mean +/- SE) and a detection limit of 4.0 microg/L (0.01 micromol/L) were obtained. Total tissue GAG amounted to 254 +/- 16 microg/g wet tissue wt in patients and 150 +/- 13 microg/g (P < 0.0001) in controls. Regarding the GAG polymers, marked differences were detected between patients and controls (chondroitin sulfate, 127 +/- 13 vs. 47 +/- 5 microg/g; hyaluronic acid, 56 +/- 5 vs. 34 +/- 4 microg/g; both P < 0.0001; dermatan sulfate, 77 +/- 6 vs. 69 +/- 6 microg/g; P < 0.05). In patients, chondroitin sulfate was the major GAG component (48 +/- 6 vs. 31 +/- 5% of total GAG in controls), whereas dermatan sulfate was dominant in controls (46 +/- 8% vs. 30 +/- 5%). The sulfated disaccharide digestion products were markedly increased (P < 0.0001) in patients, and the ratio of sulfated vs. total disaccharide content was 85 +/- 6% vs. 65 +/- 5% (P < 0.05) in patients and controls, respectively. As accumulation of negatively charged sulfate residues in GAG disaccharides results in enhanced water-binding capacity, beside inflammation and increased volume of the orbital adipose tissue, the altered structure and nature of sulfated GAG units in the orbit may be responsible for the pathogenic changes in Graves' ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199787     DOI: 10.1210/jcem.84.4.5609

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Allosteric modulators hit the TSH receptor.

Authors:  Terry F Davies; M Rejwan Ali; Rauf Latif
Journal:  Endocrinology       Date:  2014-01       Impact factor: 4.736

Review 2.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

Review 3.  The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.

Authors:  Jueyu Hou; Yunjing Tang; Yongjiang Chen; Danian Chen
Journal:  Front Cell Infect Microbiol       Date:  2021-12-22       Impact factor: 5.293

Review 4.  New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.

Authors:  Peter N Taylor; Lei Zhang; George J Kahaly; Marian Ludgate; Richard W J Lee; Ilaria Muller; Daniel G Ezra; Colin M Dayan
Journal:  Nat Rev Endocrinol       Date:  2019-12-30       Impact factor: 43.330

Review 5.  Thyrotropin receptor antibodies and Graves' orbitopathy.

Authors:  T Diana; K A Ponto; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2020-08-04       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.